Literature DB >> 1365662

Platelet adenylate cyclase activity in depression and after clomipramine and lithium treatment: relation to serotonergic function.

M E Newman1, B Lerer, P Lichtenberg, B Shapira.   

Abstract

Adenylate cyclase activity was measured in platelet membranes from 10 healthy controls, 12 depressed patients, and the same patients after treatment with clomipramine (CMI) followed by lithium carbonate (Li) supplementation, in an attempt to determine whether any evidence for an effect on the serotonergic system could be obtained in peripheral cells. There were no differences in basal, NaF-, PGE1-, or forskolin-stimulated activity either between the control subjects and depressed patients or between activities in the patients measured before treatment, after CMI, and after CMI+Li. The degree of inhibition of forskolin-stimulated adenylate cyclase by 5-HT, an effect putatively mediated by a 5-HT1A-like receptor, was not different in the depressed patients compared to controls or affected by CMI treatment, but was significantly reduced after Li supplementation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1365662     DOI: 10.1007/bf02245505

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  27 in total

1.  Brain 5-HT1 binding sites in depressed suicides.

Authors:  S C Cheetham; M R Crompton; C L Katona; R W Horton
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  The mechanisms of action of lithium. II. Effects on adenylate cyclase activity and beta-adrenergic receptor binding in normal subjects.

Authors:  E D Risby; J K Hsiao; H K Manji; J Bitran; F Moses; D F Zhou; W Z Potter
Journal:  Arch Gen Psychiatry       Date:  1991-06

3.  The 5-HT1A receptor probe [3H]8-OH-DPAT labels the 5-HT transporter in human platelets.

Authors:  J R Ieni; L R Meyerson
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

4.  Prostaglandin receptor sensitivity in psychiatric disorders.

Authors:  P D Kanof; C Johns; M Davidson; L J Siever; E F Coccaro; K L Davis
Journal:  Arch Gen Psychiatry       Date:  1986-10

Review 5.  A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence.

Authors:  P Blier; C de Montigny; Y Chaput
Journal:  J Clin Psychiatry       Date:  1990-04       Impact factor: 4.384

6.  Single and combined effects of desimipramine and lithium on serotonergic receptor number and second messenger function in rat brain.

Authors:  M E Newman; D Drummer; B Lerer
Journal:  J Pharmacol Exp Ther       Date:  1990-02       Impact factor: 4.030

Review 7.  Binding of some antidepressants to the 5-hydroxytryptamine transporter in brain and platelets.

Authors:  J O Marcusson; S B Ross
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Differential effects of electroconvulsive shock and antidepressant drugs on serotonin-2 receptors in rat brain.

Authors:  K J Kellar; C S Cascio; J A Butler; R N Kurtzke
Journal:  Eur J Pharmacol       Date:  1981-02-19       Impact factor: 4.432

9.  Effects of lithium and desimipramine on second messenger responses in rat hippocampus: relation to G protein effects.

Authors:  M E Newman; B Shapira; B Lerer
Journal:  Neuropharmacology       Date:  1991-12       Impact factor: 5.250

10.  Platelet alpha-adrenergic binding and biochemical responsiveness in depressed patients and controls.

Authors:  L J Siever; M S Kafka; S Targum; C R Lake
Journal:  Psychiatry Res       Date:  1984-04       Impact factor: 3.222

View more
  2 in total

1.  Mood stabilizer psychopharmacology.

Authors:  Todd D Gould; Guang Chen; Husseini K Manji
Journal:  Clin Neurosci Res       Date:  2002-11-14

2.  Platelet adenylate cyclase activity in Israeli victims of Iraqi Scud missile attacks with post-traumatic stress disorder.

Authors:  R Weizmann; E Gur; N Laor; A Reiss; U Muller; A Yoresh; B Lerer; M E Newman
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.